Globus Medical Inc.
GMED evidence brief
What we can confirm
- BioSniper Score:
- 8.3 / 10
- Market Cap:
- $10.03B
- Lead Asset:
- actify unicondylar knee system
What it means
What to watch
Prepared research question
What matters most for GMED—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GMED
Globus Medical Inc. (GMED) is a musculoskeletal solutions company that designs, develops, and manufactures medical devices for the orthopedic and spine markets, with a broad pipeline of surgical systems and implants.
Key risk: Competitive pressure
BioSniper Score
Based on 4 of 6 signals
Market Cap
$10.03B
Cash Runway
—
Lead Asset
actify unicondylar knee system
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 115 pipeline candidates · 2 clinical trials for Globus Medical Inc..
Globus Medical Inc. (GMED) is a musculoskeletal solutions company that designs, develops, and manufactures medical devices for the orthopedic and spine markets, with a broad pipeline of surgical systems and implants.
- Cash & equivalents of $507.7M as of 2026-06-30 [sec]
- Total revenue of $789.6M as of 2026-06-30 [sec]
- Net income of $151.6M as of 2026-06-30 [sec]
- Shareholders' equity of $4,768.6M as of 2026-06-30 [sec]
- Pipeline includes multiple spinal stabilization systems, cervical spacers, and an acetabular system [pipeline]
What works
- Strong profitability with net income of $151.6M as of 2026-06-30 [sec]
- Healthy balance sheet with shareholders' equity of $4,768.6M as of 2026-06-30 [sec]
- Broad pipeline of approved and developmental orthopedic products [pipeline]
What to weigh
- Pipeline candidate 'simplify cervical artificial disc' faces 53 competitors including major pharmaceutical firms [pipeline]
- No recent clinical trial data or regulatory milestones disclosed in available chunks [pipeline]
Risks & what to watch (2)›
Key risks
- Competitive pressure — Pipeline candidate faces 53 competitors including Johnson & Johnson and Pfizer/Viatris [pipeline]
- Limited recent disclosures — No recent clinical or regulatory updates in available chunks [pipeline]
What to watch
- Pipeline progress of spinal stabilization systems and cervical spacers [pipeline]
- Competitive dynamics in the orthopedic device market [pipeline]
- Future financial reports and revenue growth trends [sec]
Sources: News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run Globus Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Globus Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.15 · 2% dilution
Lead: Approved
115 candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 19, 2026- % of float
- 2.8%
- Days to cover
- 3.0
- Shares short
- 3,120,512
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GMED short interestGovernance
Frequently asked questions
What is the AI investment thesis for Globus Medical Inc.?
Globus Medical Inc. (GMED) is a musculoskeletal solutions company that designs, develops, and manufactures medical devices for the orthopedic and spine markets, with a broad pipeline of surgical systems and implants.
Who is the CEO of Globus Medical Inc.?
Mr. Keith W. Pfeil is the chief executive officer of Globus Medical Inc. (GMED).
Where is Globus Medical Inc. headquartered?
Globus Medical Inc. (GMED) is headquartered in Audubon, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.